263 related articles for article (PubMed ID: 32974990)
1. Characterization of Apo-Form Selective Inhibition of Indoleamine 2,3-Dioxygenase*.
Ortiz-Meoz RF; Wang L; Matico R; Rutkowska-Klute A; De la Rosa M; Bedard S; Midgett R; Strohmer K; Thomson D; Zhang C; Mebrahtu M; Guss J; Totoritis R; Consler T; Campobasso N; Taylor D; Lewis T; Weaver K; Muelbaier M; Seal J; Dunham R; Kazmierski W; Favre D; Bergamini G; Shewchuk L; Rendina A; Zhang G
Chembiochem; 2021 Feb; 22(3):516-522. PubMed ID: 32974990
[TBL] [Abstract][Full Text] [Related]
2. Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form.
Nelp MT; Kates PA; Hunt JT; Newitt JA; Balog A; Maley D; Zhu X; Abell L; Allentoff A; Borzilleri R; Lewis HA; Lin Z; Seitz SP; Yan C; Groves JT
Proc Natl Acad Sci U S A; 2018 Mar; 115(13):3249-3254. PubMed ID: 29531094
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of immunosuppressive indoleamine 2,3-dioxygenase by targeting the heme and apo-form.
Pradhan N; Akhtar N; Nath B; Peña-García J; Gupta A; Pérez-Sánchez H; Kumar S; Manna D
Chem Commun (Camb); 2021 Jan; 57(3):395-398. PubMed ID: 33326535
[TBL] [Abstract][Full Text] [Related]
4. Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1).
Röhrig UF; Reynaud A; Majjigapu SR; Vogel P; Pojer F; Zoete V
J Med Chem; 2019 Oct; 62(19):8784-8795. PubMed ID: 31525930
[TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis and Biological Evaluation of Novel 1,2,5-Oxadiazol-3- Carboximidamide Derivatives as Indoleamine 2, 3-Dioxygenase 1 (IDO1) Inhibitors.
Xia Z; Nan Y; Liu C; Lin G; Gu K; Chen C; Zhao W; Ju D; Dong X
Anticancer Agents Med Chem; 2020; 20(13):1592-1603. PubMed ID: 32496990
[TBL] [Abstract][Full Text] [Related]
6. Cell-Based Identification of New IDO1 Modulator Chemotypes.
Hennes E; Lampe P; Dötsch L; Bruning N; Pulvermacher LM; Sievers S; Ziegler S; Waldmann H
Angew Chem Int Ed Engl; 2021 Apr; 60(18):9869-9874. PubMed ID: 33565680
[TBL] [Abstract][Full Text] [Related]
7. Correlation of indoleamine-2,3-dioxigenase 1 inhibitory activity of 4,6-disubstituted indazole derivatives and their heme binding affinity.
Tsujino H; Uno T; Yamashita T; Katsuda M; Takada K; Saiki T; Maeda S; Takagi A; Masuda S; Kawano Y; Meguro K; Akai S
Bioorg Med Chem Lett; 2019 Oct; 29(19):126607. PubMed ID: 31431359
[TBL] [Abstract][Full Text] [Related]
8. What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past.
Yao Y; Liang H; Fang X; Zhang S; Xing Z; Shi L; Kuang C; Seliger B; Yang Q
J Exp Clin Cancer Res; 2021 Feb; 40(1):60. PubMed ID: 33557876
[TBL] [Abstract][Full Text] [Related]
9. Advances in the discovery and development of selective heme-displacing IDO1 inhibitors.
Sun L
Expert Opin Drug Discov; 2020 Oct; 15(10):1223-1232. PubMed ID: 32568559
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel IDO1 inhibitors targeting the protein's apo form through scaffold hopping from holo-IDO1 inhibitor.
Wu Y; Duan Q; Zou Y; Zhu Q; Xu Y
Bioorg Med Chem Lett; 2021 Nov; 52():128373. PubMed ID: 34560264
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and Molecular Modeling Studies of N'-Hydroxyindazolecarboximidamides as Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.
Lee DH; Lee JY; Jeong J; Kim M; Lee KW; Jang E; Ahn S; Lee CH; Hwang JY
Molecules; 2017 Nov; 22(11):. PubMed ID: 29120388
[TBL] [Abstract][Full Text] [Related]
12. Nitrobenzofurazan derivatives of N'-hydroxyamidines as potent inhibitors of indoleamine-2,3-dioxygenase 1.
Paul S; Roy A; Deka SJ; Panda S; Trivedi V; Manna D
Eur J Med Chem; 2016 Oct; 121():364-375. PubMed ID: 27267006
[TBL] [Abstract][Full Text] [Related]
13. Heme-containing enzymes and inhibitors for tryptophan metabolism.
Yan D; Lin YW; Tan X
Metallomics; 2017 Sep; 9(9):1230-1240. PubMed ID: 28650043
[TBL] [Abstract][Full Text] [Related]
14. Epacadostat stabilizes the apo-form of IDO1 and signals a pro-tumorigenic pathway in human ovarian cancer cells.
Rossini S; Ambrosino S; Volpi C; Belladonna ML; Pallotta MT; Panfili E; Suvieri C; Macchiarulo A; Mondanelli G; Orabona C
Front Immunol; 2024; 15():1346686. PubMed ID: 38333210
[TBL] [Abstract][Full Text] [Related]
15. Taking advantage of the interaction between the sulfoxide and heme cofactor to develop indoleamine 2, 3-dioxygenase 1 inhibitors.
Wang Y; Jia S; Chen Y; Liao X; Jie R; Jiang L; Wang T; Wen H; Gan W; Cui H
Bioorg Chem; 2024 Jul; 148():107426. PubMed ID: 38733750
[TBL] [Abstract][Full Text] [Related]
16. Diverse chemical space of indoleamine-2,3-dioxygenase 1 (Ido1) inhibitors.
Singh R; Salunke DB
Eur J Med Chem; 2021 Feb; 211():113071. PubMed ID: 33341650
[TBL] [Abstract][Full Text] [Related]
17. Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer.
Prendergast GC; Malachowski WJ; Mondal A; Scherle P; Muller AJ
Int Rev Cell Mol Biol; 2018; 336():175-203. PubMed ID: 29413890
[TBL] [Abstract][Full Text] [Related]
18. Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme.
Hamilton MM; Mseeh F; McAfoos TJ; Leonard PG; Reyna NJ; Harris AL; Xu A; Han M; Soth MJ; Czako B; Theroff JP; Mandal PK; Burke JP; Virgin-Downey B; Petrocchi A; Pfaffinger D; Rogers NE; Parker CA; Yu SS; Jiang Y; Krapp S; Lammens A; Trevitt G; Tremblay MR; Mikule K; Wilcoxen K; Cross JB; Jones P; Marszalek JR; Lewis RT
J Med Chem; 2021 Aug; 64(15):11302-11329. PubMed ID: 34292726
[TBL] [Abstract][Full Text] [Related]
19. Discovery and optimization of substituted oxalamides as novel heme-displacing IDO1 inhibitors.
Steeneck C; Kinzel O; Anderhub S; Hornberger M; Pinto S; Morschhaeuser B; Albers M; Sonnek C; Czekańska M; Hoffmann T
Bioorg Med Chem Lett; 2021 Feb; 33():127744. PubMed ID: 33333163
[TBL] [Abstract][Full Text] [Related]
20. Azole-Based Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.
Röhrig UF; Majjigapu SR; Reynaud A; Pojer F; Dilek N; Reichenbach P; Ascencao K; Irving M; Coukos G; Vogel P; Michielin O; Zoete V
J Med Chem; 2021 Feb; 64(4):2205-2227. PubMed ID: 33557523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
